Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).

Citation data:

The American journal of cardiology, ISSN: 1879-1913, Vol: 111, Issue: 9, Page: 1324-9

Publication Year:
Usage 154
Abstract Views 129
Link-outs 25
Captures 40
Exports-Saves 24
Readers 16
Social Media 3
Tweets 2
Shares, Likes & Comments 1
Citations 7
Citation Indexes 7
Repository URL:;;;;;
Goldberg, Robert J; Gurwitz, Jerry H; Saczynski, Jane S; Hsu, Grace; McManus, David D; Magid, David J; Smith, David H; Go, Alan S; CVRN PRESERVE HF Investigators
Elsevier BV
Medicine; Cardiotonic Agents; Heart Failure; Population Surveillance; Stroke Volume; Ventricular Function, Left; Cardiology; Cardiovascular Diseases; Health Services Administration; Health Services Research
Most Recent Tweet View All Tweets
article description
Limited data exist describing the differences in the medical treatment of patients with heart failure with preserved ejection fraction (HF-PEF) from those with heart failure with reduced ejection fraction (HF-REF) in more generalizable population-based cohorts. We studied patients with incident HF diagnosed from 2005 to 2008 from 4 sites participating in the Cardiovascular Research Network. These patients, their medication profile, and left ventricular systolic function status were identified from the hospital discharge and ambulatory visit diagnoses, pharmacy dispensing information, and imaging reports found in the health plan electronic databases and through chart review. The study population consisted of 6,210 patients with newly diagnosed HF-PEF and 3,914 patients with newly diagnosed HF-REF. The mean age of our study population was 73 years, 48% were women, and 74% were white. The patients with HF-REF were less likely to have been treated with various cardiac and HF-related medications before their index HF event; however, they were significantly more likely to have been treated with new cardiac medications and HF therapies after the diagnosis of HF than were the patients with HF-PEF. After controlling for several potentially confounding factors, the patients with HF-PEF were significantly less likely to have been treated with multiple cardiac drug regimens (adjusted odds ratio 0.69, 95% confidence interval 0.59 to 0.81) and multiple HF-related therapies (adjusted odds ratio 0.40, 95% confidence interval 0.38 to 0.42) than were patients with HF-REF. In conclusion, the present results from a large, population-based sample suggest considerable variation in the previous and new use of different cardiac medication classes of drugs in patients with HF-PEF versus HF-REF.